Endocrinology, Odense University Hospital, Odense, Denmark.
Scand J Public Health. 2010 Jul;38(5):502-7. doi: 10.1177/1403494810371243. Epub 2010 May 19.
This study was undertaken to assess persistence with bisphosphonates and raloxifene and to identify determinants of adherence (patient age, level of information, educational status, etc.) among women with osteoporosis in three different clinical settings in Denmark.
We compared persistence to therapy in three historical cohorts of women diagnosed with osteoporosis starting therapy between January 1999 and January 2004. The study comprised 878 patients treated and followed at Odense University Hospital, 285 patients diagnosed and followed at the Hellerup Osteoporosis Clinic (private practice), and 343 patients diagnosed at Aarhus University Hospital and followed by the referring general practitioner. Data on persistence and possible confounders were collected using a mailed questionnaire. Reminders were issued after 1-2 months to non-respondents.
Persistence at 2 years as estimated from Kaplan-Meyer analysis was 0.87, 0.84 and 0.88 in the three cohorts, respectively. There were no significant differences between the clinics. Level of persistence was not related to patient assessment of the adequacy of the clinical information provided by the prescribing doctor, presence of prior fractures or a family history of osteoporosis. However, patients who read the information leaflet on their osteoporosis medication tended to be more persistent with treatment (p < 0.09).
Women's persistence with bisphosphonates and raloxifene was surprisingly high and similar between treating centres. This may be due to a high level of public information available on osteoporosis in Denmark.
本研究旨在评估丹麦三个不同临床环境中骨质疏松症女性患者使用双磷酸盐和雷洛昔芬的持续治疗情况,并确定影响其用药依从性的因素(患者年龄、信息获取水平、教育程度等)。
我们比较了三个历史队列中女性患者的治疗持续情况,这些患者在 1999 年 1 月至 2004 年 1 月期间开始接受治疗。研究包括在奥登塞大学医院接受治疗和随访的 878 名患者、在海勒鲁普骨质疏松症诊所(私人诊所)接受诊断和随访的 285 名患者,以及在奥胡斯大学医院诊断并由转诊全科医生随访的 343 名患者。通过邮寄问卷收集了关于治疗持续时间和可能混杂因素的数据。对于未回复的患者,在 1-2 个月后会发送提醒。
从 Kaplan-Meier 分析估计,三个队列中患者在 2 年时的持续治疗率分别为 0.87、0.84 和 0.88。三个诊所之间没有显著差异。治疗的持续时间与患者对医生提供的临床信息是否充分的评估、既往骨折史或骨质疏松症家族史无关。然而,阅读骨质疏松症药物信息传单的患者往往更能坚持治疗(p < 0.09)。
女性对双磷酸盐和雷洛昔芬的持续治疗率非常高,且在治疗中心之间相似。这可能是由于丹麦有大量关于骨质疏松症的公共信息。